Tocilizumab for Giant Cell Arteritis: Clinical Outcomes Following Relapses and Tocilizumab Discontinuation Due to Adverse Events.
Nagase FN, Fukui S, Takizawa N, Yamaguchi T, Oda N, Inokuchi H, Ito T, Watanabe M, Suda M, Haji Y, Suyama Y, Rokutanda R, Minoda M, Nomura A, Uechi E, Tamaki H.
Nagase FN, et al. Among authors: watanabe m.
J Rheumatol. 2024 Nov 15:jrheum.2024-0612. doi: 10.3899/jrheum.2024-0612. Online ahead of print.
J Rheumatol. 2024.
PMID: 39547687